MX2020013335A - Metodos novedosos. - Google Patents

Metodos novedosos.

Info

Publication number
MX2020013335A
MX2020013335A MX2020013335A MX2020013335A MX2020013335A MX 2020013335 A MX2020013335 A MX 2020013335A MX 2020013335 A MX2020013335 A MX 2020013335A MX 2020013335 A MX2020013335 A MX 2020013335A MX 2020013335 A MX2020013335 A MX 2020013335A
Authority
MX
Mexico
Prior art keywords
sub
novel methods
opioid receptor
mtorc1
neuroinflammation
Prior art date
Application number
MX2020013335A
Other languages
English (en)
Inventor
Lawrence P Wennogle
Gretchen Snyder
Robert Davis
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2020013335A publication Critical patent/MX2020013335A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La divulgación proporciona métodos para el tratamiento agudo de depresión y/o ansiedad, para mejorar la señalización de mTOR (por ejemplo, mTORC1) y para la reducción de la neuroinflamación; que comprende administrar a un paciente que lo necesite, una cantidad terapéuticamente eficaz de un ligando del receptor 5-HT2A/opioide mu o del receptor 5-HT2A/D1 y/o D2/opioide mu.
MX2020013335A 2018-06-08 2019-06-07 Metodos novedosos. MX2020013335A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682554P 2018-06-08 2018-06-08
US201862780017P 2018-12-14 2018-12-14
PCT/US2019/036114 WO2019237037A1 (en) 2018-06-08 2019-06-07 Novel methods

Publications (1)

Publication Number Publication Date
MX2020013335A true MX2020013335A (es) 2021-05-27

Family

ID=68769463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013335A MX2020013335A (es) 2018-06-08 2019-06-07 Metodos novedosos.

Country Status (5)

Country Link
US (1) US20210093634A1 (es)
EP (1) EP3801527A4 (es)
CA (1) CA3102948A1 (es)
MX (1) MX2020013335A (es)
WO (1) WO2019237037A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018009158A (es) 2016-01-26 2018-11-19 Intra Cellular Therapies Inc Compuestos organicos.
CN111093665A (zh) * 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
EP3898581A4 (en) * 2018-12-17 2022-08-17 Intra-Cellular Therapies, Inc. SYNTHESIS OF CONDENSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLE
KR20210104833A (ko) * 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로사이클 융합 감마-카르볼린 합성

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237536A (zh) * 2008-03-12 2016-01-13 细胞内治疗公司 取代的杂环稠合的γ-咔啉固体
ES2602503T3 (es) * 2010-04-22 2017-02-21 Intra-Cellular Therapies, Inc. Compuestos orgánicos
IN2014DN08562A (es) * 2012-04-14 2015-05-22 Intra Cellular Therapies Inc
MX2018009158A (es) * 2016-01-26 2018-11-19 Intra Cellular Therapies Inc Compuestos organicos.

Also Published As

Publication number Publication date
CA3102948A1 (en) 2019-12-12
EP3801527A4 (en) 2022-03-30
US20210093634A1 (en) 2021-04-01
EP3801527A1 (en) 2021-04-14
WO2019237037A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MX2020009668A (es) Métodos novedosos.
MX2020013335A (es) Metodos novedosos.
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
NZ611108A (en) Methods of treating fgf21-associated disorders
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
NZ737399A (en) Ccr2 modulators
TNSN07028A1 (en) Fused ring heterocycle kinase modulators
MX2009013194A (es) Proteinas de fusion del receptor para productos finales de glicacion avanzada.
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
MY179105A (en) Methods of treating alzheimer's disease
WO2021203103A3 (en) Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
MX2021002322A (es) Nuevos metodos.
MA53711A (fr) Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
PH12021550671A1 (en) Prodrugs of cgrp antagonists
WO2018229551A3 (en) METHODS OF TREATING A DISORDER RELATED TO THE USE OF OPIOIDS